SK284255B6 - Použitie alfa-metyl-p-tyrozínu na inhibíciu produkcie melanínu v melanocytoch dúhovky - Google Patents
Použitie alfa-metyl-p-tyrozínu na inhibíciu produkcie melanínu v melanocytoch dúhovky Download PDFInfo
- Publication number
- SK284255B6 SK284255B6 SK1424-99A SK142499A SK284255B6 SK 284255 B6 SK284255 B6 SK 284255B6 SK 142499 A SK142499 A SK 142499A SK 284255 B6 SK284255 B6 SK 284255B6
- Authority
- SK
- Slovakia
- Prior art keywords
- latanoprost
- tyrosine
- methyl
- melanin
- tyrosinase
- Prior art date
Links
- 230000008099 melanin synthesis Effects 0.000 title claims description 13
- 210000002752 melanocyte Anatomy 0.000 title claims description 11
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 title description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 17
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 16
- 230000002503 metabolic effect Effects 0.000 claims abstract description 3
- 238000011458 pharmacological treatment Methods 0.000 claims abstract description 3
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 41
- 229960001160 latanoprost Drugs 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 101710147108 Tyrosinase inhibitor Proteins 0.000 claims description 3
- 239000000030 antiglaucoma agent Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 229960004317 unoprostone Drugs 0.000 claims description 2
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims description 2
- 150000003167 prostaglandin E3 derivatives Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 230000019612 pigmentation Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 15
- 210000000554 iris Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 230000036564 melanin content Effects 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229950008081 unoprostone isopropyl Drugs 0.000 description 3
- -1 -isopropyl ester Chemical class 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 210000001943 adrenal medulla Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- BORBLDJNKYHVJP-FXBDTBDDSA-N dolichodial Chemical compound C[C@H]1CC[C@H](C(=C)C=O)[C@@H]1C=O BORBLDJNKYHVJP-FXBDTBDDSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- WHNCXIBKVUPNHR-UHFFFAOYSA-N 3,4-dihydroxy-1h-indole-2-carboxylic acid Chemical compound C1=CC(O)=C2C(O)=C(C(=O)O)NC2=C1 WHNCXIBKVUPNHR-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 101100072702 Drosophila melanogaster defl gene Proteins 0.000 description 1
- 206010072289 Eye colour change Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI000939A IT1291633B1 (it) | 1997-04-22 | 1997-04-22 | Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride |
| PCT/EP1998/002365 WO1998047515A1 (en) | 1997-04-22 | 1998-04-21 | THE USE OF α-METHYL-P-TYROSINE TO INHIBIT MELANIN PRODUCTION IN IRIS MELANOCYTES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK142499A3 SK142499A3 (en) | 2000-09-12 |
| SK284255B6 true SK284255B6 (sk) | 2004-12-01 |
Family
ID=11376994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1424-99A SK284255B6 (sk) | 1997-04-22 | 1998-04-21 | Použitie alfa-metyl-p-tyrozínu na inhibíciu produkcie melanínu v melanocytoch dúhovky |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6359001B1 (it) |
| EP (1) | EP0977575B1 (it) |
| JP (1) | JP2001521540A (it) |
| KR (1) | KR20010020202A (it) |
| CN (1) | CN1255064A (it) |
| AT (1) | ATE227577T1 (it) |
| AU (1) | AU732046B2 (it) |
| CA (1) | CA2287887A1 (it) |
| DE (1) | DE69809408T2 (it) |
| DK (1) | DK0977575T3 (it) |
| ES (1) | ES2187028T3 (it) |
| HU (1) | HUP0002100A3 (it) |
| IL (1) | IL132503A (it) |
| IT (1) | IT1291633B1 (it) |
| NO (1) | NO995122L (it) |
| NZ (1) | NZ500435A (it) |
| PL (1) | PL189304B1 (it) |
| PT (1) | PT977575E (it) |
| RU (1) | RU2218159C2 (it) |
| SI (1) | SI0977575T1 (it) |
| SK (1) | SK284255B6 (it) |
| WO (1) | WO1998047515A1 (it) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4834224B2 (ja) | 1999-03-05 | 2011-12-14 | デューク ユニバーシティ | Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体 |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US9744237B2 (en) * | 2009-01-29 | 2017-08-29 | Kambiz Thomas Moazed | Method and system for effecting changes in pigmented tissue |
| WO2011011065A1 (en) * | 2009-07-22 | 2011-01-27 | Kambiz Thomas Moazed | Method and system for effecting changes in pigmented tissue |
| US20110280909A1 (en) * | 2009-01-29 | 2011-11-17 | Kambiz Thomas Moazed | Method and system for effecting changes in pigmented tissue |
| US10646552B2 (en) | 2012-01-17 | 2020-05-12 | Tyme, Inc. | Pharmaceutical compositions and methods |
| US8481498B1 (en) | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
| US20130183263A1 (en) | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
| US10272068B2 (en) | 2012-01-17 | 2019-04-30 | Tyme, Inc. | Pharmaceutical compositions and methods |
| CN104220057B (zh) | 2012-01-17 | 2017-11-03 | 迪美公司 | 药物组合物和方法 |
| US9763903B2 (en) | 2013-10-22 | 2017-09-19 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| US9326962B2 (en) | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| US9585841B2 (en) | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
| US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
| ES2738248B2 (es) * | 2018-06-21 | 2023-03-10 | Consejo Superior Investigacion | Uso de inhibidores de la tirosina hidroxilasa para el tratamiento del aneurisma de aorta |
| BR112021022784A2 (pt) | 2019-05-14 | 2022-03-22 | Tyme Inc | Composições e métodos para tratamento do câncer |
| CN116035151A (zh) * | 2023-01-18 | 2023-05-02 | 云南贝泰妮生物科技集团股份有限公司 | 一种刺梨闪释粉及其制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04117313A (ja) * | 1990-09-06 | 1992-04-17 | Kanebo Ltd | 美白化粧料 |
-
1997
- 1997-04-22 IT IT97MI000939A patent/IT1291633B1/it active IP Right Grant
-
1998
- 1998-04-21 PT PT98924164T patent/PT977575E/pt unknown
- 1998-04-21 US US09/403,524 patent/US6359001B1/en not_active Expired - Fee Related
- 1998-04-21 DE DE69809408T patent/DE69809408T2/de not_active Expired - Fee Related
- 1998-04-21 EP EP98924164A patent/EP0977575B1/en not_active Expired - Lifetime
- 1998-04-21 SK SK1424-99A patent/SK284255B6/sk unknown
- 1998-04-21 PL PL98336386A patent/PL189304B1/pl not_active IP Right Cessation
- 1998-04-21 CA CA002287887A patent/CA2287887A1/en not_active Abandoned
- 1998-04-21 CN CN98804999A patent/CN1255064A/zh active Pending
- 1998-04-21 AT AT98924164T patent/ATE227577T1/de not_active IP Right Cessation
- 1998-04-21 IL IL13250398A patent/IL132503A/en not_active IP Right Cessation
- 1998-04-21 NZ NZ500435A patent/NZ500435A/en unknown
- 1998-04-21 SI SI9830312T patent/SI0977575T1/xx unknown
- 1998-04-21 KR KR1019997009782A patent/KR20010020202A/ko not_active Application Discontinuation
- 1998-04-21 RU RU99124771/14A patent/RU2218159C2/ru not_active IP Right Cessation
- 1998-04-21 DK DK98924164T patent/DK0977575T3/da active
- 1998-04-21 WO PCT/EP1998/002365 patent/WO1998047515A1/en not_active Application Discontinuation
- 1998-04-21 HU HU0002100A patent/HUP0002100A3/hu unknown
- 1998-04-21 ES ES98924164T patent/ES2187028T3/es not_active Expired - Lifetime
- 1998-04-21 AU AU76462/98A patent/AU732046B2/en not_active Ceased
- 1998-04-21 JP JP54502598A patent/JP2001521540A/ja not_active Withdrawn
-
1999
- 1999-10-21 NO NO995122A patent/NO995122L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT977575E (pt) | 2003-03-31 |
| HUP0002100A3 (en) | 2003-05-28 |
| IT1291633B1 (it) | 1999-01-11 |
| EP0977575A1 (en) | 2000-02-09 |
| RU2218159C2 (ru) | 2003-12-10 |
| CA2287887A1 (en) | 1998-10-29 |
| PL189304B1 (pl) | 2005-07-29 |
| US6359001B1 (en) | 2002-03-19 |
| ES2187028T3 (es) | 2003-05-16 |
| ITMI970939A1 (it) | 1998-10-22 |
| NZ500435A (en) | 2001-09-28 |
| JP2001521540A (ja) | 2001-11-06 |
| PL336386A1 (en) | 2000-06-19 |
| HUP0002100A2 (hu) | 2000-11-28 |
| DK0977575T3 (da) | 2003-03-10 |
| IL132503A0 (en) | 2001-03-19 |
| ATE227577T1 (de) | 2002-11-15 |
| AU7646298A (en) | 1998-11-13 |
| DE69809408T2 (de) | 2003-07-10 |
| KR20010020202A (ko) | 2001-03-15 |
| EP0977575B1 (en) | 2002-11-13 |
| ITMI970939A0 (it) | 1997-04-22 |
| NO995122L (no) | 1999-12-21 |
| IL132503A (en) | 2004-06-20 |
| CN1255064A (zh) | 2000-05-31 |
| WO1998047515A1 (en) | 1998-10-29 |
| AU732046B2 (en) | 2001-04-12 |
| SI0977575T1 (en) | 2003-04-30 |
| DE69809408D1 (de) | 2002-12-19 |
| NO995122D0 (no) | 1999-10-21 |
| SK142499A3 (en) | 2000-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK284255B6 (sk) | Použitie alfa-metyl-p-tyrozínu na inhibíciu produkcie melanínu v melanocytoch dúhovky | |
| Morgan et al. | The effects of cAMP on differentiation of cultured Schwann cells: progression from an early phenotype (04+) to a myelin phenotype (P0+, GFAP-, N-CAM-, NGF-receptor-) depends on growth inhibition. | |
| US6300327B1 (en) | Compositions and methods for potentiation of neurotrophin activity | |
| Guenard et al. | Transforming growth factor-beta blocks myelination but not ensheathment of axons by Schwann cells in vitro | |
| CA2339218C (en) | Methods and compositions for increasing insulin sensitivity | |
| Imaizumi et al. | The influence of oxygen free radicals on the permeability of the monolayer of cultured brain endothelial cells | |
| Chvapil et al. | Local anesthetics and wound healing | |
| Maragoudakis et al. | Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties | |
| Moy et al. | Phenytoin modulates connective tissue metabolism and cell proliferation in human skin fibroblast cultures | |
| DRAGO et al. | α-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro | |
| Riley | Radicals and melanomas | |
| Lehrmann et al. | Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum | |
| AU2002364203A1 (en) | Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners | |
| Handa et al. | Minoxidil inhibits ocular cell proliferation and lysyl hydroxylase activity. | |
| Lemic‐Stojcevic et al. | Effect of azelaic acid on melanoma cells in culture | |
| Katsuki et al. | Requirement of neural activity for the maintenance of dopaminergic neurons in rat midbrain slice cultures | |
| CZ372099A3 (cs) | Použití alfa-methyl-p-tyrosinu k inhibici produkce melaninu v pigmentových buňkách duhovky | |
| Cohen et al. | Effect of N-acetyl-cis-4-hydroxyproline on collagen synthesis | |
| US6451818B1 (en) | Therapeutic use of 1,6-dimethyl-8β-hydroxymethyl-10α-methoxyergoline | |
| Schrijver et al. | 149: Biotin deficiency in the rat as a model for Leigh's syndrome | |
| JPH04234819A (ja) | 脳の老化及び中枢神経系の機能不足状態の予防及び治療のためのデルマタン硫酸の使用 | |
| CA1156148A (en) | Process for reducing depression | |
| Alcaín et al. | Ceruloplasmin releases pH-induced inhibition of cell proliferation stimulated by growth factors | |
| Freiburghaus et al. | 151: Composition of brush border membranes in several congenital intestinal enzyme deficiencies investigated by use of SDS-polyacrylamide-gel-electrophoresis | |
| Eggermont et al. | 153: Intrahepatic cholestasis and excessive formation of bile acid intermediates |